Page 20 - United Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MedCity News United Therapeutics notches another FDA approval for lung drug The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the United Therapeutics drug. The additional indication gives the company another way to grow revenue for the drug, which faces generic competition. Shares0   United Therapeutics has received FDA approval for its drug, treprostinil, as a treatment for high blood pressure affecting the lungs in patients who have a group of rare respiratory disorders called interstitial lung diseases. The regulatory nod is the second for the inhaled version of treprostinil, which was initially approved in 2009 as a treatment for pulmonary arterial hypertension high blood pressure in the arteries that carry blood from the heart to the lungs. Silver Spring, Maryland-based United Therapeutics also sells the drug in injectable and oral formulations. Together, the three ver

United statesSilver springMichael benkowitzDeka researchAmerican lung associationDevelopment corpMaryland based united therapeuticsUnited therapeuticsNew england journalUnited therapeuticSan ramonRemunity pumpWeight lossMedical devicesHealthcare innovationMedcity news